Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new Locations section lists Maryland, North Carolina, and South Carolina, replacing the previous individual location entries. The HHS Vulnerability Disclosure link has been removed, and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.4%

- Check22 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedAdded a clarifying note that publications are automatically filled from PubMed and updated the revision to v3.3.2.SummaryDifference0.1%

- Check43 days agoChange DetectedA site-wide government funding status notice has been removed. The core study details and contacts remain unchanged.SummaryDifference0.4%

- Check65 days agoChange DetectedThe Study Details page preserves the same core information as before (title, interventions, status, eligibility criteria, locations). Only minor formatting or layout adjustments are evident.SummaryDifference0.4%

- Check86 days agoChange DetectedAdded a government funding/operating-status notice and bumped version to v3.2.0, replacing the prior v3.1.0.SummaryDifference2%

- Check94 days agoChange DetectedUpgrade from v3.0.2 to v3.1.0, updating the page version identifier.SummaryDifference0.1%

Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.